Vinod Patel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Vinod Patel has a total of 191 co-authors. Here are the top co-authors by number of shared publications:
Chris Sproat
Oral Surgery Department Guy's & St Thomas' NHS Foundation Trust London UK
15 shared publicationsJerry Kwok
Department of Oral Surgery, Guy's & St Thomas' Hospital London, England, UK
10 shared publicationsMegan Burns
Department of Oral Surgery Guy's and St Thomas's NHS Foundation Trust London UK
9 shared publicationsRana Wali
Oral Surgery Registrar, Oral Surgery Department, Guy´s and St Thomas´ Hospital, London, UK
8 shared publicationsC. Sproat
Fl 23 Oral Surgery Dept Guys Dental Hospital London UK
6 shared publicationsIsabel Sassoon
Computer Science Department, Brunel University, London, Kingston Lane, Uxbridge, UB8 3PH, UK
6 shared publications
Latest Publications
- 25 November 2025
- Published by Wiley in Oral Surgery
- Vol. 19 (1) , 53-56
Upadacitinib‐Related Osteonecrosis of the Jaw
Background: Upadacitinib is a Janus kinase ( JAK ) inhibitor, part of a class of medications that modulate immune system signalling. These drugs are commonly used to manage inflammatory conditions such as rheumatoid arthritis and ulcerative colitis by reducing inflammation and pain. Methods: To our knowledge, we report the first documented case of spontaneous osteonecrosis of the jaw associated with upadacitinib. Results: In this report, we explore the drug's mechanism of action and its potential role in the pathogenesis of medication‐related osteonecrosis of the jaw (MRONJ). Conclusion: Though rare, upadacitinib should be added to the growing list of drugs implicated in MRONJ.
- 25 November 2025
- Published by Wiley in Oral Surgery
- Vol. 19 (1) , 53-56
Upadacitinib‐Related Osteonecrosis of the Jaw
Background: Upadacitinib is a Janus kinase ( JAK ) inhibitor, part of a class of medications that modulate immune system signalling. These drugs are commonly used to manage inflammatory conditions such as rheumatoid arthritis and ulcerative colitis by reducing inflammation and pain. Methods: To our knowledge, we report the first documented case of spontaneous osteonecrosis of the jaw associated with upadacitinib. Results: In this report, we explore the drug's mechanism of action and its potential role in the pathogenesis of medication‐related osteonecrosis of the jaw (MRONJ). Conclusion: Though rare, upadacitinib should be added to the growing list of drugs implicated in MRONJ.
- 14 November 2025
- Published by Springer Nature in British Dental Journal
- Vol. 239 (9) , 613-619
A literature review and update on medications related to osteonecrosis of the jaw independent of bisphosphonates and denosumab
Medication-related osteonecrosis of the jaw (MRONJ) caused by bone-modifying agents, such as bisphosphonates and denosumab, is well-established within the literature. The introduction of new medications for cancer therapy, autoimmune diseases, inflammatory diseases and bone disorders has led to further MRONJ cases being documented. As these newer therapies become more widely used, the incidence of MRONJ is expected to increase. This literature review aims to update the growing body of literature on MRONJ, focusing on the link between these novel medications and MRONJ development. These medications include tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors, monoclonal antibodies, radiopharmaceuticals, demethylation agents, selective oestrogen receptor modulators and corticosteroids. Given the increasing number of agents associated with MRONJ, it is essential for dental professionals to stay informed about these drugs and their associated risks to ensure effective management and patient care.
- 14 November 2025
- Published by Springer Nature in British Dental Journal
- Vol. 239 (9) , 613-619
A literature review and update on medications related to osteonecrosis of the jaw independent of bisphosphonates and denosumab
Medication-related osteonecrosis of the jaw (MRONJ) caused by bone-modifying agents, such as bisphosphonates and denosumab, is well-established within the literature. The introduction of new medications for cancer therapy, autoimmune diseases, inflammatory diseases and bone disorders has led to further MRONJ cases being documented. As these newer therapies become more widely used, the incidence of MRONJ is expected to increase. This literature review aims to update the growing body of literature on MRONJ, focusing on the link between these novel medications and MRONJ development. These medications include tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors, monoclonal antibodies, radiopharmaceuticals, demethylation agents, selective oestrogen receptor modulators and corticosteroids. Given the increasing number of agents associated with MRONJ, it is essential for dental professionals to stay informed about these drugs and their associated risks to ensure effective management and patient care.
- 20 May 2025
- Published by Wiley in Oral Surgery
- Vol. 18 (3) , 312-318
Management of Craniofacial Non‐Jawbone Osteoradionecrosis With Pentoxifylline, Vitamin E and Sodium Clodronate
Background: Osteoradionecrosis (ORN) often affects the jaws, but other craniofacial bones are also vulnerable to radiation damage. Studies exploring the role of pentoxifylline, vitamin E and sodium clodronate (PENTO/CLO) for the management of jaw osteoradionecrosis have shown promising results. Extrapolating from these findings, this service evaluation aims to report the clinical outcomes when medical management was employed in craniofacial non‐jawbone ORN where patients were either unsuitable for surgery or declined this option.Methods: We identified 17 patients with non‐jaw craniofacial ORN from our local patient registry. 15 out of 17 were managed with the PENTO/CLO regimen.Results: In the PENTO/CLO group, 60% (n = 9) of patients achieved disease stability, 27% (n = 4) experienced healing and 13% (n = 2) showed disease progression, primarily due to persistent infection.Conclusion: These findings suggest that PENTO/CLO therapy may be a promising option for managing craniofacial ORN, particularly in cases where surgery is not feasible. This study offers early insights into extending medical management to broader craniofacial applications, highlighting its potential as an alternative treatment strategy where limited options are available.
- 20 May 2025
- Published by Wiley in Oral Surgery
- Vol. 18 (3) , 312-318
Management of Craniofacial Non‐Jawbone Osteoradionecrosis With Pentoxifylline, Vitamin E and Sodium Clodronate
Background: Osteoradionecrosis (ORN) often affects the jaws, but other craniofacial bones are also vulnerable to radiation damage. Studies exploring the role of pentoxifylline, vitamin E and sodium clodronate (PENTO/CLO) for the management of jaw osteoradionecrosis have shown promising results. Extrapolating from these findings, this service evaluation aims to report the clinical outcomes when medical management was employed in craniofacial non‐jawbone ORN where patients were either unsuitable for surgery or declined this option.Methods: We identified 17 patients with non‐jaw craniofacial ORN from our local patient registry. 15 out of 17 were managed with the PENTO/CLO regimen.Results: In the PENTO/CLO group, 60% (n = 9) of patients achieved disease stability, 27% (n = 4) experienced healing and 13% (n = 2) showed disease progression, primarily due to persistent infection.Conclusion: These findings suggest that PENTO/CLO therapy may be a promising option for managing craniofacial ORN, particularly in cases where surgery is not feasible. This study offers early insights into extending medical management to broader craniofacial applications, highlighting its potential as an alternative treatment strategy where limited options are available.
- 27 February 2025
- Published by Elsevier in Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
- Vol. 140 (3) , 283-290
The use of oral bisphosphonates in the management of antibiotic refractory secondary chronic osteomyelitis
- 27 February 2025
- Published by Elsevier in Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
- Vol. 140 (3) , 283-290
The use of oral bisphosphonates in the management of antibiotic refractory secondary chronic osteomyelitis
- Open Access
Multi-institutional Normal Tissue Complication Probability (NTCP) Prediction Model for Mandibular Osteoradionecrosis: Results from the PREDMORN Study
Background Mandibular osteoradionecrosis (ORN) is a severe late complication affecting patients with head and neck cancer (HNC) treated with radiotherapy that significantly impacts patients’ quality of life and can require costly interventions. While radiation dose is a key factor, other clinical and demographic risk factors influence ORN development. Previous predictive models have primarily been single-institutional, limiting their generalizability. The PREDMORN Consortium was established to address these limitations. In this first analysis, we have aimed to reproduce existing statistical association and modelling analyses on the largest and most diverse mandibular ORN cohort worldwide to allow comparison with previous studies. As such, we have developed, tested and externally validated a multi-institutional normal tissue complication probability (NTCP) model for mandibular ORN. Methods This retrospective multi-institutional study included 1,184 HNC patients (389 ORN cases) from seven institutions. Clinical, demographic, and dosimetric (DVH) variables were analysed to develop a prediction model (any grade of ORN vs. no ORN) using forward stepwise logistic regression with correlation-based variable pre-selection. The ORN NTCP model was developed on 80% of data from six institutions, tested on the remaining unseen 20%, and externally validated on the seventh institution’s dataset. Results Key predictors of ORN were D30%, V70Gy, pre-RT dental extractions, and smoking status. The ORN NTCP model demonstrated good calibration and predictive performance, with AUCs of 0.69 for internal testing and external validation, which improved when tested on a sub-cohort of oropharyngeal and locally advanced larynx/hypopharynx cancer cases (AUCs of 0.75). Conclusion The PREDMORN NTCP model is the largest multi-institutional effort to predict ORN risk in HNC patients. We provide guidance on how to adjust the NTCP predicted probabilities for differences in target population baseline ORN risk to facilitate application of the model. Future research will focus on incorporating imaging-based spatial data and further external validation to enhance clinical applicability.
Open AccessMulti-institutional Normal Tissue Complication Probability (NTCP) Prediction Model for Mandibular Osteoradionecrosis: Results from the PREDMORN Study
Background Mandibular osteoradionecrosis (ORN) is a severe late complication affecting patients with head and neck cancer (HNC) treated with radiotherapy that significantly impacts patients’ quality of life and can require costly interventions. While radiation dose is a key factor, other clinical and demographic risk factors influence ORN development. Previous predictive models have primarily been single-institutional, limiting their generalizability. The PREDMORN Consortium was established to address these limitations. In this first analysis, we have aimed to reproduce existing statistical association and modelling analyses on the largest and most diverse mandibular ORN cohort worldwide to allow comparison with previous studies. As such, we have developed, tested and externally validated a multi-institutional normal tissue complication probability (NTCP) model for mandibular ORN. Methods This retrospective multi-institutional study included 1,184 HNC patients (389 ORN cases) from seven institutions. Clinical, demographic, and dosimetric (DVH) variables were analysed to develop a prediction model (any grade of ORN vs. no ORN) using forward stepwise logistic regression with correlation-based variable pre-selection. The ORN NTCP model was developed on 80% of data from six institutions, tested on the remaining unseen 20%, and externally validated on the seventh institution’s dataset. Results Key predictors of ORN were D30%, V70Gy, pre-RT dental extractions, and smoking status. The ORN NTCP model demonstrated good calibration and predictive performance, with AUCs of 0.69 for internal testing and external validation, which improved when tested on a sub-cohort of oropharyngeal and locally advanced larynx/hypopharynx cancer cases (AUCs of 0.75). Conclusion The PREDMORN NTCP model is the largest multi-institutional effort to predict ORN risk in HNC patients. We provide guidance on how to adjust the NTCP predicted probabilities for differences in target population baseline ORN risk to facilitate application of the model. Future research will focus on incorporating imaging-based spatial data and further external validation to enhance clinical applicability.
- 28 November 2024
- Published by Elsevier in Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
- Vol. 139 (4) , 439-452
Histological assessment of extensive or unresectable central giant cell granulomas treated with denosumab: a case series
- 28 November 2024
- Published by Elsevier in Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
- Vol. 139 (4) , 439-452
Histological assessment of extensive or unresectable central giant cell granulomas treated with denosumab: a case series
- 25 October 2024
- Published by Springer Nature in British Dental Journal
- Vol. 237 (8) , 645-651
An institutional protocol including socket alveoplasty and primary closure following dental extractions for patients with an elevated risk of developing medication-related osteonecrosis of the jaw
Background The purpose of this study was to evaluate the outcomes of alveoplasty and primary closure following dental extractions in patients with an elevated medication-related osteonecrosis of the jaw (MRONJ) risk. Study design A retrospective review of 46 patients with an elevated MRONJ risk was conducted. This included a total of 124 teeth extracted, due to unrestorable caries (n = 46; 37%) and peri-apical pathology (n = 44; 35%). Results Our results showed 0% (n = 0) of patients in our cohort developed MRONJ post-operatively. Most patients were being treated with intravenous zoledronic acid for breast cancer (n = 23; 50%), with an average of 15 doses (range 1-72). Conclusions This study supports the use of alveoplasty and primary closure for patients with an elevated MRONJ risk. The authors highlight the importance of pre-operative cone beam computed tomography imaging, optimisation of immune status, post-operative prophylactic antibiotics, and the delay of bone modifying agents recommencement as influential factors in mitigating risk and favouring successful outcomes.
- 25 October 2024
- Published by Springer Nature in British Dental Journal
- Vol. 237 (8) , 645-651
An institutional protocol including socket alveoplasty and primary closure following dental extractions for patients with an elevated risk of developing medication-related osteonecrosis of the jaw
Background The purpose of this study was to evaluate the outcomes of alveoplasty and primary closure following dental extractions in patients with an elevated medication-related osteonecrosis of the jaw (MRONJ) risk. Study design A retrospective review of 46 patients with an elevated MRONJ risk was conducted. This included a total of 124 teeth extracted, due to unrestorable caries (n = 46; 37%) and peri-apical pathology (n = 44; 35%). Results Our results showed 0% (n = 0) of patients in our cohort developed MRONJ post-operatively. Most patients were being treated with intravenous zoledronic acid for breast cancer (n = 23; 50%), with an average of 15 doses (range 1-72). Conclusions This study supports the use of alveoplasty and primary closure for patients with an elevated MRONJ risk. The authors highlight the importance of pre-operative cone beam computed tomography imaging, optimisation of immune status, post-operative prophylactic antibiotics, and the delay of bone modifying agents recommencement as influential factors in mitigating risk and favouring successful outcomes.
- 25 October 2024
- Published by Springer Nature in British Dental Journal
- Vol. 237 (8) , 623-628
The provision of dental extractions in patients with established or a history of medication-related osteonecrosis of the jaw
Patients with existing or a history of medication-related osteonecrosis of the jaw (MRONJ) are considered to be at a higher risk of further developing MRONJ, particularly if dental extractions are necessary. It is assumed that their underlying risk factors predispose them to developing MRONJ and they are allocated into an ‘elevated risk group'. There is no evidence to quantify this risk level; however, it has led to an avoidance of dental extractions in this cohort. However, avoidance of dental extractions is not a realistic treatment option to prevent MRONJ and there is emerging evidence that inflammatory dental disease, such as peri-apical pathology or periodontal disease, can trigger the pathogenesis of MRONJ. The current case series retrospectively reviewed 28 patients with existing or a history of MRONJ who underwent dental extractions (n = 65) via our departmental protocol, which includes elective circumferential socket alveoplasty and primary closure. Our outcomes show that MRONJ did not develop at the new extraction site, with a post-operative review period of at least six months. These results provide promising evidence that dental extractions can be performed in this group of patients with <1% risk of developing MRONJ at the new surgical site, if appropriate measures are undertaken.
- 25 October 2024
- Published by Springer Nature in British Dental Journal
- Vol. 237 (8) , 623-628
The provision of dental extractions in patients with established or a history of medication-related osteonecrosis of the jaw
Patients with existing or a history of medication-related osteonecrosis of the jaw (MRONJ) are considered to be at a higher risk of further developing MRONJ, particularly if dental extractions are necessary. It is assumed that their underlying risk factors predispose them to developing MRONJ and they are allocated into an ‘elevated risk group'. There is no evidence to quantify this risk level; however, it has led to an avoidance of dental extractions in this cohort. However, avoidance of dental extractions is not a realistic treatment option to prevent MRONJ and there is emerging evidence that inflammatory dental disease, such as peri-apical pathology or periodontal disease, can trigger the pathogenesis of MRONJ. The current case series retrospectively reviewed 28 patients with existing or a history of MRONJ who underwent dental extractions (n = 65) via our departmental protocol, which includes elective circumferential socket alveoplasty and primary closure. Our outcomes show that MRONJ did not develop at the new extraction site, with a post-operative review period of at least six months. These results provide promising evidence that dental extractions can be performed in this group of patients with <1% risk of developing MRONJ at the new surgical site, if appropriate measures are undertaken.
- 6 October 2024
- Published by Wiley in Oral Surgery
- Vol. 18 (1) , 96-108
Glandular odontogenic cyst: A case series and literature review
Aim: The glandular odontogenic cyst (GOC) is a rare odontogenic cyst with a potentially aggressive growth potential and high recurrence rate. An absence of pathognomonic clinical, radiographic and histopathological features means the glandular odontogenic cyst is rarely included in a differential diagnosis for a well‐defined radiolucent cyst or tumour of the jaw. There is an absence of clarity on the most effective method of treatment for GOCs to reduce recurrence risk.Materials and Methods: In this case series, we documented the treatment of three male patients who were referred for further investigation of well‐defined, corticated radiolucent lesions. Two lesions were located in the body of the mandible and one in the anterior maxilla. All three patients were in their fifth decade of life. Two patients reported mild discomfort, while one patient was asymptomatic upon presentation.Results: The included cases were treated conservatively with enucleation and curettage under general anaesthesia. Histological examination confirmed a diagnosis of GOC in all cases. No clinical or radiographic recurrence has been observed.Conclusion: The clinical, radiographic and histological appearance of the GOC mimics other cysts and tumours of the jaw, most significantly central mucoepidermoid carcinoma. Long‐term follow‐up is recommended due to the potential for recurrence, which is influenced by lesion size, locularity and cortical plate integrity.
- 6 October 2024
- Published by Wiley in Oral Surgery
- Vol. 18 (1) , 96-108
Glandular odontogenic cyst: A case series and literature review
Aim: The glandular odontogenic cyst (GOC) is a rare odontogenic cyst with a potentially aggressive growth potential and high recurrence rate. An absence of pathognomonic clinical, radiographic and histopathological features means the glandular odontogenic cyst is rarely included in a differential diagnosis for a well‐defined radiolucent cyst or tumour of the jaw. There is an absence of clarity on the most effective method of treatment for GOCs to reduce recurrence risk.Materials and Methods: In this case series, we documented the treatment of three male patients who were referred for further investigation of well‐defined, corticated radiolucent lesions. Two lesions were located in the body of the mandible and one in the anterior maxilla. All three patients were in their fifth decade of life. Two patients reported mild discomfort, while one patient was asymptomatic upon presentation.Results: The included cases were treated conservatively with enucleation and curettage under general anaesthesia. Histological examination confirmed a diagnosis of GOC in all cases. No clinical or radiographic recurrence has been observed.Conclusion: The clinical, radiographic and histological appearance of the GOC mimics other cysts and tumours of the jaw, most significantly central mucoepidermoid carcinoma. Long‐term follow‐up is recommended due to the potential for recurrence, which is influenced by lesion size, locularity and cortical plate integrity.